Author pages are created from data sourced from our academic publisher partnerships and public sources.
Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.
BACKGROUND The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated… Expand
Variation in plasma leptin levels in response to fasting in Antarctic fur seals (Arctocephalus gazella)
Abstract. Plasma leptin levels were determined in 8 lactating female and 20 pup Antarctic fur seals (Arctocephalus gazella) during fasting periods of normal duration. Plasma leptin levels ranged from… Expand
Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.
- Y. Anzai, S. McLachlan, M. Morris, R. Saxton, R. Lufkin
- AJNR. American journal of neuroradiology
PURPOSE To investigate dextran-coated superparamagnetic iron oxide particles (BMS 180549) as an MR contrast agent for assessing lymph nodes. METHODS Five different doses ranging from 0.3 to 1.7 mg… Expand
Genetic variation within the ticks Ixodes holocyclus and Ixodes cornuatus from south-eastern Australia.
- J. Jackson, N. Chilton, I. Beveridge, M. Morris, R. Andrews
- Biology, Medicine
- International journal for parasitology
- 1 October 2000
Ticks from mainland Australia (Victoria, New South Wales and Queensland) and Tasmania, identified morphologically as either Ixodes holocyclus or Ixodes cornuatus, were compared genetically using 24… Expand
Safety and optimum concentration of a manganese chloride–based oral MR contrast agent
- M. Bernardino, J. Weinreb, D. Mitchell, W. Small, M. Morris
- Journal of magnetic resonance imaging : JMRI
- 1 November 1994
To determine the safety of a manganese chloride‐based oral magnetic resonance (MR) contrast agent and the ideal concentration of the agent for marking in three different anatomic sites (stomach,… Expand
Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
The safety data from the phase II clinical trial of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide contrast agent, are presented. One hundred and four patients with focal liver or spleen… Expand
Splenic Imaging with Ultrasmall Superparamagnetic Iron Oxide Ferumoxtran-10 (AMI-7227): Preliminary Observations
- M. Harisinghani, S. Saini, +11 authors P. Hahn
- Journal of computer assisted tomography
- 1 September 2001
Purpose Ferumoxtran-10 (ultrasmall superparamagnetic iron oxide; Combidex, AMI-7227) is a long-circulating MR contrast agent with reticuloendothelial uptake known to enhance tissue T1 and T2… Expand
Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure
BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In response to risks associated with external delivery systems, an implantable IV infusion system was… Expand
Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial
Background The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable,… Expand
Evaluation of the Safety and Efficacy of Gadoteridol Injection (a low osmolal magnetic resonance contrast agent): Clinical Trials Report